United Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +11.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 20.9x | Better than 40% |
| Forward P/E | 19.5x | Better than 39% |
| Price / Sales | 7.5x | Better than 14% |
| P/E vs own 5-yr range | 98th pctl | Better than 5% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 18.0% | Better than 80% |
| Net income CAGR (3Y) | 22.4% | Better than 74% |
| Free cash flow CAGR (3Y) | 16.0% | Better than 60% |
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 87.9% | Better than 95% |
| Operating margin | 47.7% | Better than 97% |
| Net margin | 41.9% | Better than 96% |
| Return on equity | 19.7% | Better than 78% |
| Return on invested capital | 17.7% | Better than 87% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 8.1% | Better than 88% |
| 6-month return | -2.4% | Better than 51% |
| 12-month return (ex latest month) | 23.2% | Better than 62% |
| Distance below 52-week high | 9.7% | Better than 84% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.6x | Better than 90% |
| Debt to assets | 4.1% | Better than 82% |
| Interest coverage | 88.9x | Better than 93% |
| Free cash flow / net income | 77.6% | Better than 25% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 76.9% | Better than 56% |
| Upside to average target | 23.4% | Better than 38% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 559.10
- Open
- 561.20
- Day range
- 551.77 - 563.12
- Avg price
- 555.01
- Volume
- 531.78K
- Turnover
- 295.15M
- Turnover ratei
- 1.37%
- Volume ratioi
- 0.82
- Amplitudei
- 2.03%
- 52-week rangei
- 455.63 - 614.23
Valuation
- P/Ei
- 19.91
- P/E (TTM)i
- 20.94
- P/Bi
- 3.76
- EPSi
- 27.86
- Book value / shi
- 147.36
- Net profit
- 1.19B
- Net assets
- 6.28B
Share structure
- Market cap
- 23.63B
- Float capi
- 21.60B
- Shares out
- 42.59M
- Float sharesi
- 38.94M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
9.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-35.75M net over the window
Short interest
- Shares short
- 1.84M
- % of floati
- 4.28%
- Days to coveri
- 3.45
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of United Therapeutics (UTHR)?
United Therapeutics last traded at 554.73. This page shows a periodic quote snapshot. Check the displayed quote time.
What is United Therapeutics's market cap?
About 23.63B.
What is the P/E ratio of United Therapeutics?
The trailing twelve-month P/E is 20.94, above its own 5-year average of 16.01 — toward the top of its historical range (98.25% percentile). See the Valuation tab for the full history.
Does United Therapeutics pay a dividend?
United Therapeutics does not currently pay a regular dividend.
Is United Therapeutics a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 684.31, which implies 23.4% upside from the current price. This is not investment advice.
What is United Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates United Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
United Therapeutics discussion 0 comments